Talphera, Inc. (TLPH)
Market Cap | 18.52M |
Revenue (ttm) | 651,000 |
Net Income (ttm) | -14.20M |
Shares Out | 16.99M |
EPS (ttm) | -0.85 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 39,416 |
Open | 1.170 |
Previous Close | 1.150 |
Day's Range | 1.080 - 1.170 |
52-Week Range | 0.430 - 1.610 |
Beta | n/a |
Analysts | Strong Buy |
Price Target | 4.50 (+316.67%) |
Earnings Date | May 14, 2024 |
About TLPH
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (AR... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for TLPH stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 316.67% from the latest price.
News
Talphera to Participate at A.G.P. Virtual Healthcare Conference
SAN MATEO, Calif. , May 16, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...
Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update
First patients at multiple sites are expected to be enrolled in the NEPHRO CRRT registrational study in Q2 2024 Dr. Shakil Aslam, an expert in renal diseases, including acute kidney injury, joins Talp...
Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024
SAN MATEO, Calif., May 2, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
Company rebranding and corporate transformation to Talphera completed in Q1 2024 First patient enrollment in the NEPHRO CRRT registrational study expected in Q1 2024 with a projected PMA submission by...
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
SAN MATEO, Calif. , March 1, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies...
Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024
SAN MATEO, Calif. , Feb. 26, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapi...
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
The total committed funding is expected to provide sufficient capital to fund Talphera through a potential FDA approval of Niyad™, targeted for the first half of 2025 $16 million of total equity commi...